Fig. 1.
a Cumulative incidence of hematologic recovery (HR). Times to neutrophil (ANC) and platelet (Plt) recovery were defined as time from transplant to > 0.5 × 109/L or, 20 × 109/L and 50 × 109/L, respectively. The cumulative incidence of ANC and platelet recovery were calculated counting deaths from other causes as competing risk. b Cumulative incidence of HR according to CD34 + cells. The hematologic recovery was significantly associated with CD34 + cells (ANC > 0.5 × 109/L p = 0.04; Platelet > 0.5 × 109/L p = 0.07). Median CD34 + cells infused was 0.54 × 105/kg. c Cumulative incidence of non relapse mortality (NRM). The cumulative incidence of NRM was 20 ±9% and was calculated counting deaths from other causes as competing risk. d Cumulative incidence of relapse/progression. Cumulative incidence of relapse/progression was 56 ±10%. In the study protocol, therapy after relapse/progression was free. Two relapses were treated with a further IB-UCB transplant: one was a by phenotypic refractory Acute Leukemia, who achieved a stable complete remission lasting 9 months, then he died for leukemia. The second was a Chronic Myeloid Leukemia patient transplanted in blastic phase, relapsing after 6 months from IB-UCB transplant with hematologic relapse, central nervous system involvement and a solid mass in the breast, which completely responded to Ponatinib. She received a second IB-UCB transplant achieving a further complete remission lasting 5 months; however relapse occurred again resulting in death. e Cumulative incidence of acute GVHD, f Overall survival